Subscribe To

Price Alert Latest News Economic Calendar News

INCY / Incyte Corporation (INCY) Q3 2023 Earnings Call Transcript

Incyte Corporation (NASDAQ:INCY ) Q3 2023 Earnings Call Transcript October 31, 2023 8:00 AM ET Company Participants Ben Strain - Head of Investor Relations Herve Hoppenot - President and Chief Executive Officer Barry Flannelly - Executive Vice President and General Manager, North America Pablo Cagnoni - President and Head of Research and Development Steven Stein - Executive Vice President and Chief Medical Officer Christiana Stamoulis - Executive Vice President and Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Leonid Timashev - RBC Capital Markets David Lebowitz - Citigroup Inc. Jessica Fye - JPMorgan Chase & Co. Marc Frahm - TD Cowen Gospel Enyindah-Asonye - Morgan Stanley Matthew Phipps - William Blair & Co. Paul Jeng - Guggenheim Securities, LLC Mara Goldstein - Mizuho Securities Andrew Berens - SVB Securities Reni Benjamin - JMP Securities Operator Hello, and welcome to the Incyte Third Quarter Earnings Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation. Read More

Demo Live Account See Partner Details

Content Topics

Incyte

Corporation

INCY

2023

Earnings

Call

Transcript

incy

Stock

Posted: Oct 31 2023, 12:23

Author Name: Seeking Alpha

INCY News

By Zacks Investment Research
October 31, 2023

Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates

Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for

By Seeking Alpha
October 31, 2023

Incyte Corporation (INCY) Q3 2023 Earnings Call Transcript

Incyte Corporation (NASDAQ:INCY ) Q3 2023 Earnings Call Transcript October 31, 2023 8:00 AM ET Company Participants Ben Strain - Head of Investor Rela

By Reuters
October 31, 2023

Drugmaker Incyte's quarterly profit beats on lower costs

Incyte reported a third-quarter profit on Tuesday that beat analysts' estimates as lower costs helped offset weak sales of its blood cancer drug Jakaf

By Zacks Investment Research
October 31, 2023

Incyte (INCY) Surpasses Q3 Earnings Estimates

Incyte (INCY) came out with quarterly earnings of $1.10 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings

By Zacks Investment Research
October 13, 2023

Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why

Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.

By Zacks Investment Research
October 12, 2023

Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study

Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegme

By Business Wire
September 29, 2023

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and

By Zacks Investment Research
September 19, 2023

Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug

Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.